About Adela
Adela is a company based in San Francisco (United States) founded in 2021 by Manish Agarwal, Ishank Gupta, Daniel De Carvalho, and Scott Bratman. Adela has raised $133.97 million across 4 funding rounds from investors including LabCorp, Orbimed and RA Capital. Adela offers products and services including MRD Blood Test, Immunotherapy Monitoring Test, and Early Cancer Screening Test. Adela operates in a competitive market with competitors including Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
- Headquarter San Francisco, United States
- Founders Manish Agarwal, Ishank Gupta, Daniel De Carvalho, Scott Bratman
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Adela, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$133.97 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
LabCorp
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Adela
Adela offers a comprehensive portfolio of products and services, including MRD Blood Test, Immunotherapy Monitoring Test, and Early Cancer Screening Test.
Detects minimal residual disease post-surgery for recurrence monitoring.
Assesses responses to immunotherapy in cancer patients.
Identifies multiple cancer types through blood analysis for early detection.
People of Adela
Unlock access to complete
Unlock access to complete
Funding Insights of Adela
Adela has successfully raised a total of $133.97M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Adela
Adela has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include LabCorp, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science and technology sectors
|
Locked | Locked | Locked |
Investor details for Adela
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adela
Investment portfolio details for Adela
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Adela
Detailed financials for Adela
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adela Comparisons
Peer comparison for Adela
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adela
Adela operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Adela
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adela
Complete news archive for Adela
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adela
Adela was founded in 2021.
Adela is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Adela is a funded company, having raised a total of $133.97M across 4 funding rounds to date.
Adela was founded in 2021 in San Francisco, United States, within the biotechnology sector. A platform utilizing genome-wide methylation analysis technology is provided for early cancer detection. Blood tests are developed to identify kidney cancer and intracranial brain tumors by distinguishing informative methylated genomic regions from non-informative ones, targeting specific areas for sequencing. Operations focus on advancing diagnostic tools for oncology applications.
Adela's top competitors include Guardant Health, Juno Therapeutics and Foundation Medicine.
Adela offers MRD Blood Test, Immunotherapy Monitoring Test, and Early Cancer Screening Test.
Adela has 7 investors. Key investors include LabCorp, Orbimed, RA Capital, F-Prime Capital, and Deerfield Management Group.